Recent Updates
Recently added Catalysts
ANTX Positive Sentiment

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Wednesday, September 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: AN2 Therapeutics, Inc. has announced the granting of inducement equity awards to Dr. Cameron Trenor, its newly-appointed Chief Medical Officer. The awards include a non-qualified stock option for 233,333 shares and restricted stock units for 116,666 shares. This move is part of the company's strategy to attract and retain key talent.

Market Sentiment Analysis

POSITIVE FACTORS

  • AN2 Therapeutics appointed a new Chief Medical Officer.
  • The company is actively granting equity awards.
  • Inducement grants reflect confidence in leadership.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+371%
120-day peak, hindsight
Typical move
1.3%
average across 4 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Epetraborole
Phase 2 · Mycobacterium Abscessus Infection

Full Press Release Details

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.The inducement awards consist of a non-qualified stock option to purchase 233,333 shares of the Company’s common stock and restricted stock units representing 116,6

Frequently Asked Questions

Who is the new Chief Medical Officer of AN2 Therapeutics?

Dr. Cameron Trenor is the newly-appointed Chief Medical Officer.

What type of equity awards were granted?

The company granted a non-qualified stock option and restricted stock units.

How many shares are included in the inducement grants?

The inducement grants include options for 233,333 shares and 116,666 restricted stock units.

What is the purpose of the inducement grants?

The inducement grants aim to attract and retain key leadership talent.

ShareAdd on Google
Tags: ANTX Viatris Investor Conferences Healthcare AN2 Therapeutics Cameron Trenor inducement grants biopharmaceuticals NASDAQ: ANTX
Last updated: Sep 16, 2026

Biotech snapshot

Cash runway
$80M liquidity · $2M/mo burn
~33 mo
Minimal dilution risk
Lead asset
EpetraborolePhase 2
Mycobacterium Abscessus Infection →

Catalyst track record

+371%
best trade around ANTX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ANTX.

See every catalyst's timing & PoA →